NTRK1 and neoplasm: Several immunotherapy strategies have been tested for anti-tumor responses using monoclonal antibodies against receptor tyrosine kinases like members of the EGFR family (cetuximab, pertuzumab, and trastuzumab)15,16 or against their ligands like VEGF (bevacizumab)17, involved in tumor cell proliferation or angiogenesis, respectively.